Other languages Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-15 pm EDT			5-day change	1st Jan Change
41.55 ^USD	-0.46%		-1.63%	-17.87%

Apr. 11	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 10	Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform From Peer Perform	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome	Apr. 07
Sector Update: Health Care Stocks Gain Premarket Wednesday	Mar. 13
Ionis Pharmaceuticals' Phase 2 Study of ION224 Achieves Liver Histologic Improvement; Shares Up	Mar. 13
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial	Mar. 13
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224	Mar. 13
Ionis Pharmaceuticals, Inc. Announces Executive Changes	Feb. 29
Travere drug for rare kidney condition recommended for EU approval	Feb. 23
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	Feb. 21
Ionis Pharmaceuticals' Q4 Net Loss Narrows as Revenue Increases; Provides 2024 Revenue Guidance; Shares Gain Pre-Bell	Feb. 21
Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 21
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 30, 2023	Feb. 21
Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS	Feb. 15
GSK : une procédure accélérée dans l'hépatite aux USA	Feb. 12
Ionis Pharmaceuticals Says US FDA Grants Fast Track Designation to Eplontersen	Feb. 08
Ionis Pharmaceuticals Insider Sold Shares Worth $1,160,303, According to a Recent SEC Filing	Feb. 05
Ionis Pharmaceuticals Insider Sold Shares Worth $333,788, According to a Recent SEC Filing	Jan. 29
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study	Jan. 22
Ionis Pharma's genetic disease drug succeeds in late-stage study	Jan. 22
Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema	Jan. 22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Other languages

Filters